- Conditions
- PTSD, Trauma, Healthy
- Interventions
- fluorodeoxyglucose (FDG)-PET/MRI
- Drug
- Lead sponsor
- Zahi Fayad
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 236
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Atherosclerotic Cardiovascular Disease, Overweight, Obesity
- Interventions
- Maridebart Cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 45 Years to 99 Years
- Enrollment
- 12,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 139
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 116 more
- Conditions
- Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
- Interventions
- ETC-1002, Placebo
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
- Conditions
- Hypertension, Hyperlipidemias
- Interventions
- Penn Med Healthy Heart Program
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 1,980 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Atherosclerosis, Coronary
- Interventions
- Drug Infusion (BQ-123)
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atherosclerotic Coronary Vascular Disease
- Interventions
- Ranolazine 500 mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • New York, New York
- Conditions
- Peripheral Vascular Disease
- Interventions
- Complete SE Vascular Stent System
- Device
- Lead sponsor
- Medtronic Endovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 4
- States / cities
- Fremont, California • Gainesville, Florida • Ocala, Florida + 1 more
- Conditions
- Myocardial Ischemia
- Interventions
- Not listed
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 10
- States / cities
- Huntsville, Alabama • Mobile, Alabama • San Jose, California + 7 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- University of Oxford
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 16,124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2049
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
- Interventions
- Olezarsen, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 43
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Greenwich, Connecticut + 32 more
- Conditions
- Coronary Artery Disease
- Interventions
- Cleerly Labs and Cleerly ISCHEMIA
- Device
- Lead sponsor
- Cleerly, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Huntington Park, California • San Diego, California + 18 more
- Conditions
- Atherosclerosis, Hyperlipidemia, Hypertension, Diabetes Mellitus
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, Placebo I A (for NNC0385-0434 A 15 mg), NNC0385-0434 A 100 mg, Placebo I A (for NNC0385-0434 A 40 mg), Placebo II A (for NNC0385-0434 A 100 mg), Evolocumab 140 mg/mL, Repatha®
- Drug · Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Palm Springs, California • Boca Raton, Florida • Fort Lauderdale, Florida + 9 more
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- Evolocumab, Placebo, Statin therapy
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 20 more
- Conditions
- Thoracic Aortic Aneurysm, Penetrating Ulcers
- Interventions
- Relay Thoracic Stent-Graft
- Device
- Lead sponsor
- Bolton Medical
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 12 more
- Conditions
- Type 2 Diabetes, Overweight, ASCVD
- Interventions
- Dulaglutide, Semaglutide, Tirzepatide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60,000 participants
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psoriasis, Atherosclerotic Cardiovascular Disease, Obesity, Dyslipidemia, Cardiometabolic Diseases
- Interventions
- Niagen, Placebo
- Dietary Supplement · Other
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cardiovascular Disease
- Interventions
- Olpasiran, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Boca Raton, Florida • Atlanta, Georgia + 7 more
- Conditions
- Peripheral Arterial Disease, Critical Limb Ischemia
- Interventions
- Serranator, POBA
- Device
- Lead sponsor
- Cagent Vascular LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Atherosclerotic Lesions in the Aortorenal Ostium
- Interventions
- Express™ Renal Premounted Stent System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 14
- States / cities
- Sarasota, Florida • Peoria, Illinois • Springfield, Illinois + 10 more
- Conditions
- Atherosclerosis
- Interventions
- Not listed
- Lead sponsor
- Piedmont Healthcare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, Dyslipidemia, Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (Stage 3)
- Interventions
- Low-dose Colchicine at 0.5mg daily, Usual Care
- Drug · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas